Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalbuphine extended release - Trevi Therapeutics

Drug Profile

Nalbuphine extended release - Trevi Therapeutics

Alternative Names: Haduvio; Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Penwest Pharmaceuticals
  • Developer Endo Pharmaceuticals; MentiNova; Rutgers; Trevi Therapeutics
  • Class Analgesics; Antipruritics; Antitussives; Morphinans; Opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Prurigo nodularis; Pruritus
  • Phase II Cough
  • No development reported Drug-induced dyskinesia
  • Discontinued Pain

Most Recent Events

  • 07 May 2024 US FDA approves IND application for phase Ib respiratory physiology trial of Nalbuphine extended release in Idiopathic pulmonary fibrosis
  • 07 May 2024 Trevi Therapeutics plans a phase Ib respiratory physiology trial for Idiopathic pulmonary fibrosis patients in USA in third quarter of 2024
  • 28 Mar 2024 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA (PO, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top